TGF-β as a promising option in the treatment of multiple sclerosis

被引：57
作者：
Mirshafiey, Abbas [1 ]
Mohsenzadegan, Monireh [1 ]
机构：
[1] Univ Tehran Med Sci, Sch Publ Hlth, Dept Immunol, Tehran 14155, Iran
来源：
NEUROPHARMACOLOGY | 2009年 / 56卷 / 6-7期
关键词：
TGF-beta; Multiple sclerosis; EAE; T cell; GROWTH-FACTOR-BETA; REGULATORY T-CELLS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; NECROSIS-FACTOR-ALPHA; TRANSFORMING GROWTH-FACTOR-BETA-1; IN-VITRO; 1,25-DIHYDROXYVITAMIN D-3; SYNOVIAL INFLAMMATION; SIGNALING PATHWAYS;
D O I：
10.1016/j.neuropharm.2009.02.007
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
Transforming growth factor-beta (TGF-beta) is a potent regulatory cytokine with diverse effects on hemopoietic cells. The pivotal function of TGF-beta in the immune system is to maintain tolerance via the regulation of lymphocyte proliferation, differentiation, and survival. Among T cells, CD4(+)CD25(+)FOXP3(+) T regs contain the main source of TGF-beta that suppresses immune responses in inflammatory sites. Defects in TGF-beta 1 expression or its signaling in T cells correlate with the onset of several autoimmune diseases. Thus, understanding the function and regulation of TGF-beta during immune responses offers therapeutic promise for the control of autoimmune diseases such as multiple sclerosis. However, the main mechanism by which TGF-beta exerts its protective effects on the experimental model of multiple sclerosis remains to be elucidated. Paradoxically. TGF-beta 1 also acts as a pro-inflammatory cytokine and induces interleukin 17-producing pathogenic T helper cells (Th IL-17 cells) synergistically during an inflammatory response in which interleukin 6 is produced. In this review, we will describe the regulatory and therapeutic effects of TGF-beta in multiple sclerosis. (C) 2009 Elsevier Ltd, All rights reserved.
引用
收藏
页码：929 / 936
页数：8
相关论文
共 120 条
[51]   In vivo effect of interferon-β 1a on interleukin-12 and TGF-β1 cytokines in patients with relapsing-remitting multiple sclerosis [J].
Losy, J ;
Michalowska-Wender, G .
ACTA NEUROLOGICA SCANDINAVICA, 2002, 106 (01) :44-46
[52]   Glia-dependent TGF-β signaling, acting independently of the TH17 pathway, is critical for initiation of murine autoimmune encephalomyelitis [J].
Luo, Jian ;
Ho, Peggy P. ;
Buckwalter, Marion S. ;
Hsu, Tiffany ;
Lee, Lowen Y. ;
Zhang, Hui ;
Kim, Dae-Kee ;
Kim, Seong-Jin ;
Gambhir, Sanjiv S. ;
Steinman, Lawrence ;
Wyss-Coray, Tony .
JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (11) :3306-3315
[53]   Transforming growth factor-β as a regulator of site-specific T-cell inflammatory response [J].
Lúovíksson, BR ;
Gunnlaugsdóttir, B .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2003, 58 (02) :129-138
[54]  
MALYAK M, 1998, J IMMUNOL, V158, P136
[55]   Cellular mechanisms of fatal early-onset autoimmunity in mice with the T cell-specific targeting of transforming growth factor-β receptor [J].
Marie, Julien C. ;
Liggitt, Denny ;
Rudensky, Alexander Y. .
IMMUNITY, 2006, 25 (03) :441-454
[56]  
Mattner F, 2000, EUR J IMMUNOL, V30, P498, DOI 10.1002/1521-4141(200002)30:2<498::AID-IMMU498>3.3.CO
[57]  
2-H
[58]   Novel immunosuppressive therapy by M2000 in experimental multiple sclerosis [J].
Mirshafiey, A ;
Matsuo, H ;
Nakane, S ;
Rehm, BHA ;
Koh, CS ;
Miyoshi, S .
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 2005, 27 (02) :255-265
[59]   Venom therapy in multiple sclerosis [J].
Mirshafiey, Abbas .
NEUROPHARMACOLOGY, 2007, 53 (03) :353-361
[60]   Novel Promising Therapeutic Agents in Multiple Sclerosis [J].
Mirshafiey, Abbas .
RECENT PATENTS ON INFLAMMATION & ALLERGY DRUG DISCOVERY, 2007, 1 (03) :218-224
12345678910